# Tahamtan Ahmadi

> Tahamtan "Tahi" Ahmadi, M.D., Ph.D., is Genmab's Executive Vice President and Chief Medical Officer, Head of Experimental Medicines. An Iranian-German U.S. citizen based in the Philadelphia area, he trained in medicine and immunology in Germany, served on the University of Pennsylvania's hematology and oncology faculty, and then moved into industry. At Janssen he led global development of daratumumab and contributed to the clinical development and initial FDA submission for ibrutinib. He joined Genmab in 2017, became CMO in 2021, and now works across research, discovery, regulatory, and medical activities as the company builds a more integrated biotechnology operation around antibody medicines.

- **Role:** Executive Vice President and Chief Medical Officer, Head of Experimental Medicines at Genmab
- **Organizations:** Genmab, Janssen Research & Development, University of Pennsylvania
- **Nationality:** Iranian-German; U.S. citizen
- **Education:** M.D., University of Cologne, Ph.D. in immunology, University of Freiburg
- **Known for:** Led global development of daratumumab at Janssen, including clinical R&D and medical affairs strategy across indications., Was instrumental in the clinical development and initial FDA NDA submission for ibrutinib., Helped scale Genmab's fully integrated R&D enterprise after joining the company in 2017.

## Career timeline

- **Before 2012** — Served on the faculty of the Department of Hematology and Oncology at the University of Pennsylvania.
- **2012-2017** — Led experimental medicine and early development oncology at Janssen and served on its Oncology Senior Leadership Team.
- **2017** — Joined Genmab, later serving as Senior Vice President, Head of Oncology.
- **2021-03** — Became Executive Vice President and Chief Medical Officer, Head of Experimental Medicines at Genmab, with responsibility spanning research, discovery, regulatory, and medical activities.
- **2024** — Publicly framed Genmab's ProfoundBio acquisition as a combination of complementary antibody expertise and teams.
- **2025-12** — Welcomed Merus colleagues after Genmab's acquisition, emphasizing the addition of scientific talent and a more diversified, wholly owned pipeline.
- **2026-01** — Outlined Genmab's effort to build a more scalable, efficient, and digitally enabled R&D engine, including a partnership with Anthropic.
- **2026-06** — Highlighted Genmab research presented at ASCO and EHA and credited the scientists and researchers behind the work.

## Achievements

- Led global development of daratumumab at Janssen, including clinical R&D and medical affairs strategy across indications.
- Was instrumental in the clinical development and initial FDA NDA submission for ibrutinib.
- Helped scale Genmab's fully integrated R&D enterprise after joining the company in 2017.
- Appointed in 2021 to a newly created CMO role spanning research, discovery, regulatory, and medical activities.
- Co-authored scientific work published in journals including The New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, and Blood.

## Latest updates

- **2026-06** — Thanked researchers and Genmab colleagues after presentations at ASCO 2026 and EHA 2026, describing knowledge sharing as central to scientific progress.
- **2026-04** — Shared leadership lessons from an internal Genmab discussion, emphasizing openness, questions, relationships, resilience, and shared purpose.
- **2026-01** — Discussed Genmab's next phase at the J.P. Morgan Healthcare Conference and in a STAT-sponsored article, including greater program ownership and agentic AI in R&D and clinical development.
- **2025-12** — Welcomed Merus colleagues as Genmab completed the acquisition and added bispecific antibody platforms and late-stage programs.
- **2025-06** — Marked EHA 2025 by emphasizing collaboration, antibody research, and the role of shared scientific discussion.

## Links

- Website: https://www.genmab.com/about/executive-committee/tahamtan-ahmadi
- LinkedIn: https://www.linkedin.com/in/tahamtan-ahmadi-9364a428

---

Profile page: https://yespress.io/tahamtan-ahmadi
Published by YesPress — https://yespress.io
Last updated: 2026-08-11